Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes.

Mills KA, Mari Z, Pontone GM, Pantelyat A, Zhang A, Yoritomo N, Powers E, Brandt J, Dawson TM, Rosenthal LS.

Parkinsonism Relat Disord. 2016 Dec;33:107-114. doi: 10.1016/j.parkreldis.2016.09.025. Epub 2016 Sep 27.

PMID:
27733275
2.

The impact of oculomotor functioning on neuropsychological performance in Huntington disease.

Carvalho JO, Long JD, Westervelt HJ, Smith MM, Bruce JM, Kim JI, Mills JA, Paulsen JS; PREDICT-HD Investigators And Coordinators Of The Huntington Study Group.

J Clin Exp Neuropsychol. 2016;38(2):217-26. doi: 10.1080/13803395.2015.1101054.

PMID:
26745770
3.

Motor onset and diagnosis in Huntington disease using the diagnostic confidence level.

Liu D, Long JD, Zhang Y, Raymond LA, Marder K, Rosser A, McCusker EA, Mills JA, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

J Neurol. 2015 Dec;262(12):2691-8. doi: 10.1007/s00415-015-7900-7. Epub 2015 Sep 26.

4.

Multivariate clustering of progression profiles reveals different depression patterns in prodromal Huntington disease.

Kim JI, Long JD, Mills JA, McCusker E, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Neuropsychology. 2015 Nov;29(6):949-60. doi: 10.1037/neu0000199. Epub 2015 May 25.

5.

Performance of the 12-item WHODAS 2.0 in prodromal Huntington disease.

Kim JI, Long JD, Mills JA, Downing N, Williams JK, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Eur J Hum Genet. 2015 Nov;23(11):1584-7. doi: 10.1038/ejhg.2015.11. Epub 2015 Mar 4.

6.

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.

Huntington Study Group Reach2HD Investigators.

Lancet Neurol. 2015 Jan;14(1):39-47. doi: 10.1016/S1474-4422(14)70262-5. Epub 2014 Nov 14.

PMID:
25467848
7.

Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.

Paulsen JS, Long JD, Ross CA, Harrington DL, Erwin CJ, Williams JK, Westervelt HJ, Johnson HJ, Aylward EH, Zhang Y, Bockholt HJ, Barker RA; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Lancet Neurol. 2014 Dec;13(12):1193-201. doi: 10.1016/S1474-4422(14)70238-8. Epub 2014 Nov 3.

8.

Synaptic dysregulation in a human iPS cell model of mental disorders.

Wen Z, Nguyen HN, Guo Z, Lalli MA, Wang X, Su Y, Kim NS, Yoon KJ, Shin J, Zhang C, Makri G, Nauen D, Yu H, Guzman E, Chiang CH, Yoritomo N, Kaibuchi K, Zou J, Christian KM, Cheng L, Ross CA, Margolis RL, Chen G, Kosik KS, Song H, Ming GL.

Nature. 2014 Nov 20;515(7527):414-8. doi: 10.1038/nature13716. Epub 2014 Aug 17.

9.

WHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric disease.

Downing NR, Kim JI, Williams JK, Long JD, Mills JA, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Eur J Hum Genet. 2014 Aug;22(8):958-63. doi: 10.1038/ejhg.2013.275. Epub 2013 Dec 11.

10.

Tracking motor impairments in the progression of Huntington's disease.

Long JD, Paulsen JS, Marder K, Zhang Y, Kim JI, Mills JA; Researchers of the PREDICT-HD Huntington's Study Group.

Mov Disord. 2014 Mar;29(3):311-9. doi: 10.1002/mds.25657. Epub 2013 Oct 21.

11.

Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study.

Epping EA, Mills JA, Beglinger LJ, Fiedorowicz JG, Craufurd D, Smith MM, Groves M, Bijanki KR, Downing N, Williams JK, Long JD, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

J Psychiatr Res. 2013 Oct;47(10):1423-31. doi: 10.1016/j.jpsychires.2013.05.026. Epub 2013 Jun 19.

12.

Regional atrophy associated with cognitive and motor function in prodromal Huntington disease.

Aylward EH, Harrington DL, Mills JA, Nopoulos PC, Ross CA, Long JD, Liu D, Westervelt HK, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

J Huntingtons Dis. 2013;2(4):477-89. doi: 10.3233/JHD-130076.

13.

A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease.

HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network.

JAMA Neurol. 2013 Jan;70(1):25-33. doi: 10.1001/2013.jamaneurol.382.

PMID:
23108692
14.

Development of the Huntington disease work function scale.

Brossman B, Williams JK, Downing N, Mills JA, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

J Occup Environ Med. 2012 Oct;54(10):1300-8. doi: 10.1097/JOM.0b013e31825f30ab.

15.

Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease.

Smith MM, Mills JA, Epping EA, Westervelt HJ, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group.

Neuropsychology. 2012 Sep;26(5):664-9. doi: 10.1037/a0029218. Epub 2012 Jul 30.

16.

Cognitive domains that predict time to diagnosis in prodromal Huntington disease.

Harrington DL, Smith MM, Zhang Y, Carlozzi NE, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group.

J Neurol Neurosurg Psychiatry. 2012 Jun;83(6):612-9. doi: 10.1136/jnnp-2011-301732. Epub 2012 Mar 26.

17.

Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial.

Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG; ADAPT Research Team.

Int J Geriatr Psychiatry. 2012 Apr;27(4):364-74. doi: 10.1002/gps.2723. Epub 2011 May 10.

18.

Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation.

Chiang CH, Su Y, Wen Z, Yoritomo N, Ross CA, Margolis RL, Song H, Ming GL.

Mol Psychiatry. 2011 Apr;16(4):358-60. doi: 10.1038/mp.2011.13. Epub 2011 Feb 22. No abstract available.

19.

Diffuse abnormality of low to moderately organized white matter in schizophrenia.

Reading SA, Oishi K, Redgrave GW, McEntee J, Shanahan M, Yoritomo N, Younes L, Mori S, Miller MI, van Zijl P, Margolis RL, Ross CA.

Brain Connect. 2011;1(6):511-9. doi: 10.1089/brain.2011.0041.

20.

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER, Factor S, Geschwind MD, Hodgeman K, Kayson E, Noonberg S, Pourfar M, Rabinowitz K, Ravina B, Sanchez-Ramos J, Seely L, Walker F, Feigin A; Huntington Disease Study Group DIMOND Investigators.

Arch Neurol. 2010 Feb;67(2):154-60. doi: 10.1001/archneurol.2009.334. Erratum in: Arch Neurol. 2010 Apr;67(4):492. Dimebon in Subjects With Huntington Disease (DIMOND)Investigators of the Huntington Study Group [corrected to Huntington Disease Study Group DIMOND Investigators].

Supplemental Content

Loading ...
Support Center